Supernus Pharmaceuticals, Inc.

including Tricendi, which you've guided to, Oxceller and so forth. Would you agree that Calgary sales could maybe more than double, if not almost triple this year? And if that's the case, I know you're not trying to provide guidance, but directionally speaking, if that's the case, then is it fair to assume Calgary sales should accelerate on a quarterly basis going forward? That's just the root of my question. Thank you.

Yeah, the short answer is yes. I mean, we do expect Calgary to accelerate as the year goes on, and especially, of course, as we also get closer to the back-to-school season on top of all that. Yes, it is more than double than last year. That's an easy answer, actually, given last year's performance. And We've made several comments this quarter and even the last quarter, obviously, about the different dynamics in the marketplace that are helping us and are expected to continue to fuel the growth behind the brand. From the market itself being a very healthy market, the ADHD market, then clearly, from a managed care perspective, continued improvement on the coverage, the continued increase in the WACC, average, you know, wholesale acquisition cost, and of course, the expansion in our sales force and so forth, and the improved coverage from an ADHD market perspective. So all these are pointing and aligned in one direction, which is really continue to push Calvary and increase the momentum and the growth behind the product. Thank you, Jack.

Okay. One moment for our next question. Next question comes from David Ansellum of Piper Sandler. Your line is now open.